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MINIREVIEW
Bound to activate: conformational consequences
of cyclin binding to CDK2
The cyclin-dependent kinases (CDKs) are among the most highly regulated
enzymes in the protein-kinase family. The crystal structures of cyclin A
and the CDK2-cyclin A complex spectacularly reveal the atomic basis for
regulation of these enzymes and provide a template for understanding the
function and regulation of other members of the CDK family.
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Among the vast complexities of mammalian cell biology,
some of the most fascinating are the processes that con-
trol cell division. Critical to these processes are a family
of protein kinases whose catalytic subunits are homo-
logous to p34cdc2 (referred to as CDC2 hereafter) and
whose regulatory subunits display homology to cyclin
(cyc) [1]. These proteins orchestrate the process of cell
division, serving as switches that allow the transition of
the cell from one phase to the next. Whereas
CDC2-cycB is critical for regulation of the G2/M-
phase transition, CDK2-cycE and CDK2-cycA are
essential for progression through G1/S and S phase of the
cell cycle, respectively. In addition to CDC2 and CDK2,
the CDK family is now known to comprise several other
members, all of which are involved in maintaining
stringent control over cellular proliferation [2,3].
Unlike the cyclins, whose name originally reflected the
cyclic nature of their expression and degradation patterns
in vivo, the levels of CDC2 and CDK2 remain constant
throughout the cell cycle [4]. Regulation of their activi-
ties relies on both their physical association with known
regulatory subunits, and their state of phosphorylation
[5]. Thus, although the CDKs are among the smallest of
the protein kinases, consisting of little more than the
conserved catalytic core [6], the physiological regulation
of these enzymes is perhaps the most elaborate yet
appreciated for any protein kinase.
In vivo, activation of the CDKs is a concerted stepwise
process. In the case of CDK2, the monomeric catalytic
subunit is inactive when first synthesized. The initial step
in the subsequent activation process is assembly with
cyclin, a positive or activating regulatory subunit. Only
when the inactive CDK2 associates specifically with its
cyclin partner is it a substrate for phosphorylation of a
conserved threonine at' the active site, and this
phosphorylation is essential for full activity [5].
CDK2-cycA, as well as other CDK-cyclin complexes,
can be potently inhibited by a family of low molecular
weight cell-cycle-inhibitor proteins that include p21,
p27, and p16. Of these, p16, a specific inhibitor of
CDK4-cycD and CDK6-cycD, has been demonstrated
to be a tumor suppressor [7,8]. In addition, CDK2 exists
in complexes containing Rb, E2F, and proliferating cell
nuclear antigen (PCNA) [9,10], further exemplifying the
diversity of control mechanisms imparted upon this
family of protein kinases.
To understand the molecular basis for cell division
requires an understanding of the molecular features of
these enzymes and their regulatory subunits. What is the
structure of each component both in the presence and
absence of regulators? A major step in this direction was
the elucidation of the crystal structure of CDK2 in 1993
[11]. The folding of the CDK2 core was almost the same
as that of the catalytic subunit of cAMP-dependent
protein kinase (cAPK), solved previously [12,13],
although several key features were either folded differ-
ently or were disordered. A comparison of the structures
of the catalytic subunit of cAPK, containing a bound
inhibitor peptide, with that of free CDK2, suggested that
assembling these disordered parts of the molecule into a
conformation capable of supporting substrate recognition
and catalysis requires input from the cyclin. Two new
structures, a CDK2-cyclin A complex reported by Jeffrey
et al. [14] and the structure of cyclin A alone, reported in
this issue of Structure by Brown et al. [15], represent a
major new step in our understanding of this process. For
the first time we see how a protein kinase interacts with
its regulatory subunit. With these structures of cyclin A
and a CDK2-cyclin A complex, we not only understand
the molecular features of another major component, the
cyclin, but we also can begin to understand the confor-
mational flexibility of these proteins, how molecular
recognition is achieved, and how one protein induces
major conformational changes in its partner. Although
this is an essential part of understanding how these
enzymes work, this information has, until now, been
lacking for any protein kinase.
CDK2
CDKs are some of the smallest known members of the
protein-kinase family [6]. As summarized in Figure 1,
CDK2 includes primarily the conserved kinase core
with no extension at the N terminus and a short exten-
sion of 12 residues at the C terminus. There is also a
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Fig. 1. A comparison of CDK2 with the
catalytic subunit of cAMP-dependent
protein kinase (cAPK). The general
domain structure of the two proteins is
compared, with the small ATP binding
lobe in purple and the large lobe in pink.
The residues that are conserved through-
out the protein-kinase family are indi-
cated. Activating phosphorylation sites
are indicated as green circles and
inhibitory sites are pink circles. The insert
in CDK2 is shown in yellow. Myr refers
to the myristylation site. The conserved
GXGXXG motif corresponds to a glycine-
rich loop between -strands 1 and 2.
small insert within the core. CDK2 alone is inactive; for
its regulation, both positive and negative, it depends on
interactions with other accessory molecules. The phos-
phorylation state of CDK2 is also critical for its regula-
tion. CDK2 consists of two lobes; the small lobe
comprises a single helix (containing a conserved
PSTAIRE sequence) and a highly conserved five
stranded 3 sheet. In contrast, the large lobe is dominated
by a conserved core consisting of six ot helices and a
small 3 sheet that is located at the cleft interface. The
single insert in the large lobe is localized at a surface
loop between two helices and reaches up close to the
cleft interface. The insert does not, however, interfere
with the overall folding of the core.
ATP binds predominantly to the small lobe, at the base of
the cleft between the two lobes, where catalysis takes
place. Substrate is thought to bind to the surface of the
large lobe, at the edge of the cleft; residues C terminal to
the phosphoryl transfer site in the substrate peptide appear
to be particularly important determinants of peptide
recognition [16]. Distributed throughout the kinase core
are a series of invariant residues. Most of these residues
cluster at the active site, around the cleft interface, and are
important for ATP binding and for catalysis [17].
Structure of free CDK2
The structure of CDK2 alone, unphosphorylated and
inactive, shown in Figure 2, revealed several important
features, in addition to confirming that the protein-
kinase fold was conserved [11]. The ATP-binding pocket
at the base of the cleft, for example, was intact and capa-
ble of nucleotide binding, although the ATP phosphates
were oriented in such a way that direct in-line transfer of
the phosphate could not occur. In addition, two regions
in this structure, one in the small and the other in the
large lobe, were also folded in a way that was incompati-
ble with catalysis. The eight invariant residues can be
considered as constellations for the protein-kinase family,
their positions being fixed in each kinase [18-20]. All of
these residues are correctly positioned in CDK2
(Fig. 2c), with the exception of Glu51. This residue,
located in the helix of the small lobe, is part of a
conserved triad comprising a lysine in 3-strand 3 of the
small lobe, and an aspartate, in the large lobe, that binds
the activating magnesium ion bridging the 13 and y phos-
phate. This triad serves to anchor the phosphates of ATP
[21,22]. The ion pair formed between the glutamate and
the lysine couples the 13 sheet and the helix, an essential
interaction for active conformation. In the structure of
free CDK2, this helix is twisted such that the side chain
of Glu51 points into the solvent and away from Lys33.
Most of the large lobe in free CDK2, with the exception
of the insert, could be superimposed readily with the
large lobe of the catalytic subunit of cAPK. One critical
region; however, was not oriented in a conformation that
allowed for catalysis. This segment lies between two con-
served residues: Asp145, that chelates the activating mag-
nesium ion that bridges the and y phosphates of ATP,
and Glu172, that forms a buried ion pair with Arg274,
another conserved residue near the end of the kinase
core. The equivalent region in cAPK, Asp184 to Glu208,
includes 13-strand 9 (188-191), a region that was previ-
ously called the activation loop (residues 192-197), and
the P+1 loop (residues 198-205). In this review we shall
refer to this entire region, which shows considerable
variability when active and inactive kinases are compared,
as the activation segment [19]. In free CDK2 this region
includes the L12 helix (residues 147-151) and the T loop
(residues 152-162) [11].
Figure 2 highlights those regions of CDK2 that are folded
differently from the corresponding regions in the core of
the catalytic subunit of cAPK. The B factors reflect a
measure of how strongly atoms are localized. B factors of
10-20 A2 are generally associated with atoms that are well
localized with strong electron density. B values above 50,
on the other hand, indicate atoms positioned in weak,
diffuse, electron density. Such atoms are often disordered
or marginally localized. When one looks at the B factors
of the Cot backbone of CDK2 (Fig. 2b), immediately
another feature of this structure becomes apparent. This
activation segment in free CDK2 is not only folded
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Fig. 2. General features of the CDK2 structure. (a) The Ca backbone of CDK2, with the positions of the invariant residues shown in
Figure 1 highlighted as yellow, and white (glycine residues in the glycine-rich loop) spheres. Regions that are ordered differently from
the catalytic subunit of cAPK when the two structures are superimposed, that is, the activation segment in the large lobe and the
polypeptide chain linking p-strand 3 with the helix in the small lobe, are indicated in white. ATP and the conserved PSTAIRE segment
in the helix of the small domain are in yellow. The insert is in red. The activating phosphorylation site, Thr160, is shown as a green
sphere and the inhibitory site at Tyr15 is in red. (b) Ca backbone trace with each a-carbon color coded with respect to its B factor. The
scale for the color coding is also indicated.(c) Eight of the conserved residues (yellow spheres in (a)) in CDK2 and the ternary complex
of the catalytic subunit of cAPK. The two structures were superimposed using the large lobe; only the Cas are shown (spheres). The
numbering corresponds to residues in cAPK with the exception of E51 in CDK2 which is highlighted in red. The corresponding num-
bers for CDK2 are indicated in Figure 1. In the circle is the triad that is important for docking the phosphates of MgATP. The three con-
served glycines are not included as this glycine-rich loop is rather mobile. All figures were generated using the INSIGHT II program
(Biosym Technologies, Inc.).
differently, such that it covers the substrate-binding
pocket, but the region corresponding specifically to the
T loop is also relatively disordered. Thus, in solution, this
region is potentially somewhat mobile. In the small lobe
there are several regions that also have high B factors,
although the helix itself has low B factors, as does ATP.
The conserved glycine-rich loop, for example, has high B
factors, although this segment is ordered poorly in most
of the kinase structures. The segment that links -strand 3
and the helix, and immediately precedes the PSTAIRE
sequence, also has unusually high B factors.
Cyclin A
The structure of the cyclin A, both alone and in the
complex, actually corresponds to a stable proteolytic
cyclin fragment. This fragment (residues 173-432)
includes the 'cyclin box' (approximately equivalent to
the first 100 amino acids of the fragment) and contains
all the features that are necessary for binding to, and
subsequent activation of, CDK2 [23,24]. Cyclin A is a
helical protein, with one of the most immediately sur-
prising features being that it comprises two more-or-
less identical motifs, each motif corresponding to a
novel five-helix bundle. This was not predicted from
any of the previous genetic analyses and sequence com-
parisons, since the sequence identity was only 12%
between the gene-duplicated regions, and all of the
cyclin-binding activity was contained in the cyclin box.
On the basis of this structure and previous biochemical
and genetic studies, it was also possible to identify some
of the major features of the CDK-binding site. Classi-
cally, the cyclins (A and B) display five invariant residues
located within the cyclin box. Two (Lys266 and
Glu295) are surface residues and are thus good
candidates for interacting directly with CDK2. The
other three residues (Leu255, Asp240, and Arg211) are
more buried and are thus more likely to be important
for domain stabilization. For example, Asp240 and
Arg211 form a buried ion pair between helices 1 and
2, and substitution of either of these two residues for
alanine has been shown to disrupt the CDK2-binding
properties of cyclin A [23].
CDK2-cyclin A complex
The complex of CDK2 and the cyclin A box, shown in
Figure 3, defines the docking surface between the two
molecules. When this complex is compared with the
structure of each free component one can also begin to
appreciate the ordered steps in the activation process.
Binding of cyclin A to CDK2 leads to a major confor-
mational change in CDK2, whereas the structure of the
cyclin box barely changes. One cannot say whether the
cyclin-box domain will change its position relative to the
remainder of the cyclin molecule once it binds to CDK2,
as the N terminus of the cyclin is missing from the struc-
ture determination. On the basis of these two structures,
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Fig. 3. Structure of the CDK2-cyclin A complex. (a) The structure of CDK2 is indicated in purple and the two domains of cyclin A are
shown in turquoise and blue. The interacting surfaces are highlighted as follows. In CDK2, the activation loop, that includes the T loop
and the PSTAIRE helix, is white. Hydrophobic residues are pink; charged residues are yellow. Specific residues contributing to the
interface between CDK2 and cyclin A are shown as well as some of the key residues in CDK2 (Glu38 and Glu40) and cyclin (Leu255,
Asp240 and Arg211) that were thought previously to be important for CDK2-cyclin interaction. The phosphorylation site, Thrl 60, is
shown in red. (b) A close up view of the interaction site.
however, binding of cyclin induces a conformational
change in CDK2, forcing it into what appears to be a
more active conformation. There are several components
to this induced conformational change. The primary
docking event is likely to be interaction of the cyclin box
with the helix in the small lobe. Accompanying changes
in the activation segment leave the complex poised for
the next step in the activation process, the activating
phosphorylation of Thr160 by CAK, the heterologous
activating protein kinase [5]. The specific changes in each
lobe are summarized below.
Conformational changes in the small lobe
The major change in this ATP-binding domain of
CDK2 on binding of cyclin A is a reorientation of the
two major elements of secondary structure, the sheet
and the helix (Fig. 4). The global change is that the
helix containing the PSTAIRE sequence is twisted and
Fig. 4. Conformational changes in the small lobe. (a) The backbones of CDK2 (turquoise) and CDK2-cyclin A (purple) are superim-
posed. The side chains of lle49, Arg50, Glu51 and Lys 33 for CDK2-cyclin A are in yellow and for CDK2 alone are in red. The back-
bone of Lys33 in the complex is also shown in yellow to mark the position of this residue. (b) The side chains of Glu51, Lys33 and
Asp145 are shown with three a-carbons indicated as spheres. cAPK is in turquoise; CDK2 is in pink, with the position of Glu51
highlighted in red; the CDK2-cyclin A complex side chains are in yellow.
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pushed up against the sheet. Three key residues
(Ile49-Glu5l) in this helix undergo critical reorientation
upon cyclin binding, and the importance of each was
predicted. Glu51 is one of the eight invariant residues in
the protein-kinase family (Fig. 2), and it is the only one
that was not aligned in the structure of CDK2 in the
absence of cyclin. Instead of binding to Lys33, it was
facing the solvent. By binding to the helix, cyclin causes
the helix to twist such that it moves into the cleft, allow-
ing Glu51 to pair with Lys33. The P sheet and the helix,
are now tethered to one another, and the essential
Lys33, Glu51, Asp145 triad is complete. Two other
residues in the PSTAIRE sequence change significantly
when cyclin binds. Ile49 becomes a major contact point
at the CDK2-cyclin interface and Arg50, predicted to
be a potential ligand for Thrl60, is now in position to
interact with the phosphate. Thus, each residue in this
turn of the helix is playing a major role. A second conse-
quence of pushing this helix into place up against the
3 sheet and closer to the cleft interface is that this move-
ment also dislodges the activation segment. With the
small lobe properly assembled, it is no longer possible for
this segment to assume the conformation that it has in
the free CDK2 structure.
Conformational changes in the large lobe
Cyclin interacts with both lobes, and this was, in general,
predicted [25,26]. A comparison of the CDK2 structure
with that of cAPK suggested that conformational
changes occurred in the activation loop on cyclin bind-
ing. The specific changes in this region are shown in Fig-
ure 5. In the absence of cyclin, 3-strand 9, a conserved
feature in nearly all of the other kinase structures that
have been solved so far, is missing. Instead of the
3 strand, there is a small helix, the L12 helix. This helix,
followed by the T loop, is part of the activation segment
that folds up over the cleft and reaches up to the helix in
the small lobe. 13-strand 6 in the large lobe is in position
but unpaired. As a consequence of cyclin binding, the
T12 helix melts and is replaced by 13-strand 9, which
moves down to pair with 3-strand 6, on one side, and
cyclin, on the other. The T loop now follows the back-
bone of cAPK much more closely. The B factors in this
T-loop region differ very significantly between the
bound and unbound forms of CDK2 (Fig. 5). Whereas
the entire T loop has very high B factors in the CDK2
structure, much of the T loop is now well ordered in the
complex. The exception is the small segment flanking
Thrl60, where the B factors are still high. In cAPK the
B factors for this entire region are low.
The next step in the activation process is the phosphoryla-
tion of Thrl60, which is now pointing away from the
active site and is poised for interaction with CAK, that
leads to activation of the complex. Following phosphory-
lation, it is predicted that this phosphorylated residue will
move into the active-site cleft, forming contacts with sev-
eral basic residues (Fig. 5). There is precedence for this
type of phosphorylation-induced conformational change
in glycogen phosphorylase in which, before phosphoryla-
tion, the arginine three residues downstream of the phos-
phorylation site is a dominant structural determinant
whereas the phosphoserine assumes the dominant role
once phosphorylation occurs [27]. For CDK2 in the
absence of the phosphate, Glu162 is the dominant residue
that fills this cationic pocket. It occupies the site that will
presumably be filled eventually by phosphorylated Thr160.
As a consequence of the cyclin-induced conformational
changes, the basic residues that will provide a docking site
for this phosphate, as they do in cAPK, are now all in
place. Arg126 and Arg150 are homologous to Arg165 and
Lys189 in cAPK and are positioned similarly in both
CDK2 structures. In the catalytic subunit of cAPK, His87
from the small lobe forms a contact with Thr197. In
CDK2, Arg50 from the PSTAIRE sequence appears to fill
this role. It is one turn further down the helix than His87
Fig. 5. Comparison of the activation segments in CDK2, cAPK, and the CDK2-cyclin complex. (a) The activation segments flanked by the
conserved residues corresponding to Asp184 and Glu208 in cAPK are shown for CDK2 (cyan), cAPK (blue), and the CDK2-cyclin A
complex (purple). The large lobes of these structures were superimposed, but only the segments between the equivalent of Aspl 84 and
Glu208 in cAPK are shown. The ta-carbons of the phosphorylation sites and the conserved aspartates and glutamates that flank the activa-
tion loops, are shown as spheres. (b) The B factors for each of these loops. The color coding for the B factors is the same as in Figure 2.
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in cAPK, but it fills similar space as its guanidinium side
chain is larger. Once phosphorylation occurs, the gluta-
mate will presumably move out of this pocket and be
replaced by phosphorylated Thrl60 that will now be the
major organizing feature of this surface. Because the cychin
box spans both lobes of the kinase core, right at the cleft
interface, it is also possible that cyclin itself contributes
directly to the recognition of some substrate proteins.
Predictions
These three structures provide, for the first time, a
window through which we can begin to glimpse and
understand how predictive tools can be used in the
future. In the absence of a high-resolution structure, we
must rely on other tools to predict which residues are
important and how they might interact with regulatory
molecules and substrates. With these structures of cyclin
A and the CDK2-cyclin A complex, we can begin to
evaluate the reliability of our predictions. Sequence
alone highlights the regions that are potentially impor-
tant for function, when the sequences for members of
large gene families are available for comparison. With
the human genome sequencing moving ahead rapidly,
there is an enormous database of information. Thus, on
the basis of sequence alignments, the conserved residues
thought to be important for CDK2 and cyclin function
were recognized [23]. Genetic manipulation of the
sequence, identifying phenotypic variants, site-directed
mutagenesis, deletion analysis, and charge-to-alanine
scanning mutagenesis, as well as protein chemistry, can
also be used to correlate specific sites and residues with
specific functions. When this information is coupled
with structure solutions of the individual components,
one can begin to predict how two proteins might dock.
Because the structures of cyclin A and the CDK2-cyclin
A complex came out more-or-less simultaneously, there
was not time to predict docking. Several invariant
residues in cyclin, however, (Fig. 3) were thought to be
important for binding to CDK2. Two of these, Lys266
and Glu295, are in close proximity on the surface and
are indeed major contact points at the interface between
CDK2 and cyclin A. The other three residues, Asp240,
Arg211 and Leu255, are buried, and their role is less
clear. Asp240 and Arg211 form an ion pair that links
two helices and are probably important for structure
even though they are far from the binding interfaces
[23]. Leu255 also is not at the interaction site and is
buried in a hydrophobic pocket. On the basis of the
structure of cAPK, models of the active form of CDK2
were also predicted [25,26]. This structure, coupled with
results from charge-to-alanine scanning mutagenesis, for
example, mapped out with quite good accuracy some of
the sites of interaction between CDK2 and cyclin. The
acidic clusters preceding the helix in the small lobe, for
example, were thought to be important for the binding
activity of CDK2 and, as seen in Figure 3, these
residues, including Glu38 and Glu40, are indeed right at
the CDK2-cyclin A interface. As structures of more
protein kinases as well as their regulatory subunits are
solved, the accuracy of modeling will only improve.
Brown et al. [15] also highlighted the importance of the
THREADER program, a computer program which
scores the energy imparted on a given sequence threaded
into a template structure. A striking feature among
cyclins is their low degree of sequence similarity yet their
ability to bind to and support activation of distinct CDKs
which themselves are highly conserved. Using the
THREADER program, with the cyclin fold as a tem-
plate, several proteins were identified that display no
apparent sequence similarity to cyclin, yet are predicted
to adopt a similar tertiary fold. TFIIB, p107 and p35
were predicted to have domains with the cyclin fold.
Among these, only the neuronal-specific p3 5 [28-30] has
been shown to bind to and activate a CDK (CDK5);
however, the primary binding determinants in cyclin A
are not conserved in p35, and, consequently, it has not
been considered to be a cyclin. The prediction that
TFIIB contains a cyclin-fold motif was dramatically con-
firmed with the subsequent report of the structure of the
core domain of TFIIB by Bagby et al. [31]. The implica-
tions of the structural similarities between a transcription
factor and the cell-cycle regulatory proteins have yet to
be resolved.
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